| Autor: |
Benson, Constance A., Williams, Paige L., Currier, Judith S., Holland, Fiona, Mahon, Laura F., MacGregor, Rob Roy, Inderlied, Clark B., Flexner, Charles, Neidig, Judith, Chaisson, Richard, Notario, Gerard F., Hafner, Richard |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 11/1/2003, Vol. 37 Issue 9, p1234-1243, 10p |
| Abstrakt: |
This multicenter, randomized, open-label phase 3 clinical trial compared the safety and efficacy of 3 clarithromycin-containing combination regimens for the treatment of disseminated Mycobacterium avium complex (MAC) disease in persons with acquired immunodeficiency syndrome. A total of 160 eligible patients with bacteremic MAC disease were randomized to receive clarithromycin with either ethambutol (C+E), rifabutin (C+R), or both (C+E+R) for 48 weeks. After 12 weeks of treatment, the proportion of subjects with a complete microbiologic response was not statistically significantly different among treatment arms: the proportion of patients with complete or partial responses who experienced a relapse while receiving C+R (24%) was significantly higher than that of patients receiving C+E+R (6%; P = .027) and marginally higher than that of patients receiving C+E (7%; P = .057). Subjects in the C+E+R group had improved survival, compared with the C+E+R group had improved survival, compared with the C+E group (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.23–0.83 and the C+R group (HR, 0.49; 95% CI, 0.26–0.92). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
